1 / 8

Tuberculosis Vaccine Market - Latest Advancements & Market Outlook 2018 to 2026

Tuberculosis (TB) is a highly contagious disease caused by the bacterium known as Mycobacterium tuberculosis and is mostly spread through person to person contact. It causes multisystem infection and eventually might lead to death of the infected person. Two types of TB that are commonly observed include latent TB in which the infected person do not show symptoms and active TB in which the infected person shows clinical symptoms of TB.

AlbertR
Télécharger la présentation

Tuberculosis Vaccine Market - Latest Advancements & Market Outlook 2018 to 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Tuberculosis Vaccine Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018–2026 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

  2. REPORT DESCRIPTION Tuberculosis Vaccine Market Overview Tuberculosis (TB) is a highly contagious disease caused by the bacterium known as Mycobacterium tuberculosis and is mostly spread through person to person contact. It causes multisystem infection and eventually might lead to death of the infected person. Two types of TB that are commonly observed include latent TB in which the infected person do not show symptoms and active TB in which the infected person shows clinical symptoms of TB. Clinical symptoms and signs of TB include fever, night sweats, cough, weight loss, hemoptysis (coughing up blood-stained sputum), fatigue, chest pain, and shortness of breath. Depending upon the symptoms, TB may be classified as pulmonary TB, subcutaneous TB or military TB. Depending on the resistance it shows, TB may be multidrug resistant TB or extended drug resistant TB. Diagnosis of tuberculosis can be carried out using skin test, polymerase chain reaction test or interferon-gamma release assays. Initial treatment regime for active TB includes drugs such as ethambutol, pyrazinamide, isoniazid, and rifampicin. Although currently no TB vaccine is approved commercially, children are vaccinated with BCG vaccine as a part of precautionary measure. However, BCG vaccine has limited utility and variable efficacy in both adults and children. Many TB vaccines are under the stage of clinical development, which are expected to reach the market in the near future. To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/1602 © Coherent market Insights. All Rights Reserved

  3. REPORT DESCRIPTION Tuberculosis Vaccine Market Dynamics Tuberculosis account for the highest amount of death caused due to infectious disease across the globe. According to the World Health Organization (WHO) factsheet 2018 on TB, 10.4 million people fell ill with TB in 2016 and 1.7 million people with TB died in the same year. More than 95% of TB deaths occur in low- and middle-income economies. Deaths caused due to TB also includes death of 0.4 million people infected with HIV. Such high number of patients across the world confirms the enormity of disease and urgent requirements for vaccines worldwide. Therefore, the launch of tuberculosis vaccine would gain significant revenue and in turn, would propel the market growth. According to a global report on tuberculosis vaccine in 2018, TB costs around US$ 21 billion annually to global economy. Another important impetus to tuberculosis vaccine market would be current complex drug regime and resistance TB has created to this drug regime. TB patient has to take more than 2-3 drugs for prolonged time period of 6 months in order to suppress the infection. Often this results in the poor patient compliance and eventually leads to drug resistance incidence which further deteriorate the TB. According to WHO, there were nearly 600,000 new cases with resistance to rifampicin antibiotic, which was the most effective first-line drug in 2017, of which around 490,000 had MDR-TB globally. If effective steps won’t be taken by 2050, MDR-TB alone could cost the world US$ 16.7 trillion as per global report on tuberculosis vaccine 2018. Drug toxicity due to high daily dose and prolonged treatment is another concern with current TB drugs. Although the cost of TB drug is not much of concern in developing economies due to government support and free medication, it is a matter of concern in developed countries such as the U.S. and Europe Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1602 © Coherent market Insights. All Rights Reserved

  4. REPORT DESCRIPTION Tuberculosis Vaccine Market - Regional Insights TB is most prevalent in middle and low income economies in Asia Pacific and Africa and therefore, these regions would represent greatest opportunity for the potential TB vaccine. According to the World Health Organization factsheet 2018 on TB, countries such as India, China, Indonesia, Philippines, Pakistan, Nigeria, and South Africa account for around 64% of the total TB deaths. Another risk factor for these regions is the high number of HIV positive population living in this region. Around 40% of deaths among HIV-positive people were due to TB in 2016 as per WHO. Tuberculosis vaccine could prove most beneficial for these regions and in turn, would drive growth of tuberculosis vaccine market. Government initiatives and international support to curb TB incidence would speed up the vaccine development and also would support access for such vaccines. Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/1602 India, which accounts for half a million global TB deaths has launched National Strategic Plan (NSP) for TB Elimination 2017-2025 to combat TB. India also formed India TB Research Consortium to boost TB vaccine and medication research. Developed regions such as North America accounts for significant number of TB patients. According to the Centre for Disease Control, a total of 9,093 TB cases were reported in the U.S. in 2017. MDR-TB and XDR-TB accounted for approximately US$ 160,000 and US$ 513,000 respectively for treatment of each patient. Effective vaccine against TB would gain significant traction in countries such as the U.S. © Coherent market Insights. All Rights Reserved

  5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

  6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

  7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

  8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved

More Related